1-20 of 33
John Lunec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6588: Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile

Maria Ahn, Luke Bevan, Ildiko Buck, Celine Cano, Juan Castro, Ben Cons, Jane Endicott, Lynsey Fazal, Nicola Ferrari, Ian Hardcastle, Keisha Hearn, Rhian Holvey, Steven Howard, Chris Johnson, Claire Jennings, Justyna Kucia-Tran, Suzanne Kyle, John Lunec, John Lyons, Duncan Miller, David Rees, Martin Noble, David R. Newell, Judith Reeks, Harpreet Saini, Jeffrey St. Denis, Emiliano Tamanini, Huw Thomas, Neil Thompson, Mladen Vinkovic, George Ward, Nicola Wallis, Hugh Walton, Stephen Wedge, Pamela Williams, Elaine Willmore, Nicola Wilshire, Yan Zhao, Gianni Chessari
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6588.
https://doi.org/10.1158/1538-7445.AM2024-6588
Published: 22 March 2024
View article titled, Abstract 6588: Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile
Journal Articles

Abstract 3333: Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index

Elaine Willmore, Maria Ahn, Suzanne Kyle, Yan Zhao, Huw Thomas, Kenneth S. Rankin, Luke Bevan, Lynsey Fazal, Keisha Hearn, Nicola Wilsher, Justyna Kucia-Tran, Nicola Ferrari, Nicola Wallis, Neil Thompson, John Lyons, Duncan Miller, Celine Cano, Martin E. Noble, Ian R. Hardcastle, Steven Howard, Gianni Chessari, John Lunec, David R. Newell, Steve R. Wedge
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3333.
https://doi.org/10.1158/1538-7445.AM2024-3333
Published: 22 March 2024
View article titled, Abstract 3333: Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index
Journal Articles

Abstract 3034: TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

Chiao-En Wu, Tsin Shue Koay, Yi-Hsuan Ho, Penny Lovat, John Lunec
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3034.
https://doi.org/10.1158/1538-7445.AM2019-3034
Published: 01 July 2019
View article titled, Abstract 3034: <em>TP53</em> mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
Journal Articles

Abstract 1870: The anti-proliferative and pro-apoptotic effect of MDM2-p53 antagonists evaluated in human tumor cells lines and chronic lymphocytic leukemia patient samples

Elaine Willmore, Yan Zhao, Carmela Ciardullo, Laura Woodhouse, Huw D. Thomas, Maria Ahn, Lynsey Fazal, Martin E. Noble, Ian Hardcastle, Steven Howard, Gianni Chessari, John Lunec, Steve Wedge
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1870.
https://doi.org/10.1158/1538-7445.AM2018-1870
Published: 01 July 2018
View article titled, Abstract 1870: The anti-proliferative and pro-apoptotic effect of MDM2-p53 antagonists evaluated in human tumor cells lines and chronic lymphocytic leukemia patient samples
Journal Articles

Abstract 2151: Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells

Chiao-En Wu, Arman Esfandiari, Yi-Hsuan Ho, Colin Shepherd, Ahmed Khairallah Mahdi, Erhan Aptullahoglu, John Wen-Cheng Chang, Penny Lovat, John Lunec
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2151.
https://doi.org/10.1158/1538-7445.AM2017-2151
Published: 01 July 2017
View article titled, Abstract 2151: Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells
Journal Articles

Abstract LB-300: In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma

Lindi Chen, Fabio Pastorino, Philip Berry, Jennifer Bonner, Katrina Wood, Gareth Veal, Mirco Ponzoni, John Lunec, David R. Newell, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): LB-300.
https://doi.org/10.1158/1538-7445.AM2017-LB-300
Published: 01 July 2017
View article titled, Abstract LB-300: In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in <em>TP53</em> wild-type orthotopic models of neuroblastoma
Journal Articles

Abstract 3701: Transcriptomic consequences of MDMX (MDM4) oncoprotein expression knockdown in MDMX-amplified breast cancer cells

Yi-hsuan Ho, Claire Hutton, Herbie Newell, John Lunec
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3701.
https://doi.org/10.1158/1538-7445.AM2016-3701
Published: 15 July 2016
View article titled, Abstract 3701: Transcriptomic consequences of MDMX (MDM4) oncoprotein expression knockdown in MDMX-amplified breast cancer cells
Journal Articles

Abstract 5263: Assessment and targeting of the MDM2-p53 network in CLL

Laura Woodhouse, Clark Crawford, Scott Marshall, Nick Bown, Jonathan Wallis, Geoffrey Summerfield, Elaine Willmore, John Lunec
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5263.
https://doi.org/10.1158/1538-7445.AM2015-5263
Published: 01 August 2015
View article titled, Abstract 5263: Assessment and targeting of the MDM2-p53 network in CLL
Journal Articles

Abstract 1785: Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner

Arman Esfandiari, Nicola J. Curtin, John Lunec
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1785.
https://doi.org/10.1158/1538-7445.AM2015-1785
Published: 01 August 2015
View article titled, Abstract 1785: Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner
Journal Articles

Abstract 5451: Profiling inhibitors of MDM2:p53 and MDMX:p53 in relation to MDMX protein levels

Sue Tudhope, Yan Zhao, Anita Wittner, Elaine Wilmore, Annalisa Bertoli, Santosh Adhikari, Suzannah J. Harnor, Fabio Del Bello, Alessandro Piergentili, John Lunec, Ian R. Hardcastle, Roger J. Griffin, Bernard R. Golding, Celine Cano, David R. Newell, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5451.
https://doi.org/10.1158/1538-7445.AM2014-5451
Published: 01 October 2014
View article titled, Abstract 5451: Profiling inhibitors of MDM2:p53 and MDMX:p53 in relation to MDMX protein levels
Journal Articles

Abstract 919: Design and preclinical pharmacological evaluation of a cleavable succinate ester solubilizing group for isoindolinone MDM2-p53 protein-protein interaction inhibitors

Yan Zhao, Huw Thomas, Junfeng Liu, Timothy J. Blackburn, Sarah Cully, Anna F. Watson, Ian R. Hardcastle, Bernard T. Golding, Roger J. Griffin, John Lunec, David R. Newell
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 919.
https://doi.org/10.1158/1538-7445.AM2012-919
Published: 15 April 2012
View article titled, Abstract 919: Design and preclinical pharmacological evaluation of a cleavable succinate ester solubilizing group for isoindolinone MDM2-p53 protein-protein interaction inhibitors
Journal Articles

Abstract 5580: Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP): A predictive biomarker of chemotherapy response in osteosarcoma

Swethajit Biswas, Kenneth Rankin, Anna Long, Sohail Nisar, Craig Gerrand, Petra Dildey, John Lunec
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 5580.
https://doi.org/10.1158/1538-7445.AM2012-5580
Published: 15 April 2012
View article titled, Abstract 5580: Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP): A predictive biomarker of chemotherapy response in osteosarcoma
Journal Articles

Abstract 612: MDMX expression is linked with MYCN amplification or expression in neuroblastoma, and sensitizes cells to MDM2-p53 antagonists

Laura D. Gamble, Deborah A. Tweddle, John Lunec
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 612.
https://doi.org/10.1158/1538-7445.AM2011-612
Published: 15 April 2011
View article titled, Abstract 612: MDMX expression is linked with <em>MYCN</em> amplification or expression in neuroblastoma, and sensitizes cells to MDM2-p53 antagonists
Journal Articles

Abstract 4529: Cellular pharmacokinetic and activity studies with the MDM2-p53 inhibitor Nutlin-3

Yan Zhao, Huw Thomas, John Lunec, David R. Newell
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4529.
https://doi.org/10.1158/1538-7445.AM10-4529
Published: 15 April 2010
View article titled, Abstract 4529: Cellular pharmacokinetic and activity studies with the MDM2-p53 inhibitor Nutlin-3
Journal Articles

p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma

Lindi Chen, Nunzio Iraci, Samuele Gherardi, Laura D. Gamble, Katrina M. Wood, Giovanni Perini, John Lunec, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2010) 70 (4): 1377–1388.
https://doi.org/10.1158/0008-5472.CAN-09-2598
Published: 14 February 2010
View article titled, p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma
Open the PDF for p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract #3446: MYCN interaction with the p53/MDM2/p14ARF network in neuroblastoma and response to p53-MDM2 antagonists

Laura Gamble, Deborah Tweddle, John Lunec
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3446.
Published: 01 May 2009
View article titled, Abstract #3446: MYCN interaction with the p53/MDM2/p14<sup>ARF</sup> network in neuroblastoma and response to p53-MDM2 antagonists
Journal Articles

Abstract #4716: Characterisation of cell lines selected for resistance to MDM2-p53 binding antagonists

Junfeng Liu, Xiaohong Lu, Ian Hardcastle, David Newell, John Lunec
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4716.
Published: 01 May 2009
View article titled, Abstract #4716: Characterisation of cell lines selected for resistance to MDM2-p53 binding antagonists
Journal Articles

Abstract #3447: Evidence that p53 is a direct transcriptional target of MYCN in neuroblastoma

Lindi Chen, Nunzio Iraci, Giovanni Perini, John Lunec, Deborah Tweddle
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3447.
Published: 01 May 2009
View article titled, Abstract #3447: Evidence that p53 is a direct transcriptional target of MYCN in neuroblastoma
Journal Articles

The development and evaluation of novel monoclonal antibodies to folate receptor alpha and folylpolyglutamate synthetase for use on paraffin embedded samples

Amy Smith, Michael Pinkney, Nigel Piggott, Ali Kucukmetin, Richard Edmondson, Alan Calvert, Ian Milton, John Lunec
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): LB-167.
Published: 01 May 2007
View article titled, The development and evaluation of novel monoclonal antibodies to folate receptor alpha and folylpolyglutamate synthetase for use on paraffin embedded samples
Journal Articles

Cell cycle targets of MYCN identified by gene expression microarray

Emma Bell, John Lunec, Deborah Tweddle
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4446.
Published: 01 May 2007
View article titled, Cell cycle targets of MYCN identified by gene expression microarray